Neoadjuvant Treatment Associated With Maintenance Therapy by Anti-PD1 Immunotherapy in Patients With Resectable Head and Neck Mucosal Melanoma

Condition:   Resectable Head and Neck Mucosal Melanomas
Interventions:   Drug: Pembrolizumab;   Procedure: Surgery;   Radiation: IMRT
Sponsor:   Gustave Roussy, Cancer Campus, Grand Paris
Not yet recruiting

http://ift.tt/2yyRNvt